Antinociceptive activity of chemical congeners of improgan: Optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic

Neuropharmacology

Volumn 51, Issue 3, 2006, Pages 447-456

  Hough, Lindsay B ^a   de Esch, Iwan J P ^b   Janssen, Elwin ^b   Phillips, James ^c   Svokos, Konstantina ^a   Kern, Brian ^a   Trachler, Jennifer ^a   Abood, Mary E ^d   Leurs, Rob ^b   Nalwalk, Julia W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c Curragh Chemistries   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Analgesic; Antinociception; Cannabinoid; CB1 receptor; Cimetidine; Improgan; Opioid

Indexed keywords

ALKYL GROUP; ANALGESIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CC 10; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); IMPROGAN; NALTREXONE; OPIATE ANTAGONIST; RIMONABANT; SULFUR 35; UNCLASSIFIED DRUG; VUF 5420; VUF 5651; VUF 5733; VUF 6912; VUF 6913; VUF 6914;

AGONIST; ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANALGESICS, NON-NARCOTIC; ANIMALS; BEHAVIOR, ANIMAL; CELL LINE; CIMETIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, CANNABINOID; SULFUR ISOTOPES;

EID: 33747048640     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.04.003     Document Type: Article

References (36)

1. 1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem. Pharmacol. 53 (1997) 207-214
2. Bannoura M.D., Nalwalk J.W., Tang Y., Carlile M., Leurs R., Menge W.M.P.B., Timmerman H., and Hough L.B. Absence of antinociceptive tolerance to improgan, a cimetidine analog, in rats. Brain Res. 814 (1998) 218-221
3. 2-antihistaminics. 19. Synthesis and H2-antihistaminic effects of N alpha-substituted histamine]. Arch. Pharm. (Weinheim) 317 (1984) 455-459
4. Burger A., Bernabe M., and Collins P.W. 2-(4-imidazolyl)cyclopropylamine. J. Med. Chem. 13 (1970) 33-35
5. A receptors. Life Sci. 75 (2004) 2551-2558
6. Cooper D.G., Young R.C., Durant G.J., and Ganellin C.R. Histamine receptors. Comp. Med. Chem. 3 (1990) 323-421
7. Crane L.A., and Glick S.D. Simple cannula for repeated intracerebral drug administration in rats. Pharmacol. Biochem. Behav. 10 (1979) 799-800
8. D'Amour F.E., and Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72 (1941) 74-79
9. 2-receptor antagonist cimetidine. J. Med. Chem. 20 (1977) 901-906
10. Eddy N.B., and Leimbach D. Synthetic analgesics, II Dithienylbutenyl and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107 (1953) 385-393
11. Frederickson R.C.A., Burgis V., and Edwards J.D. Hyperalgesia induced by naloxone follows diurnal rhythm in responsivity to painful stimuli. Science 198 (1977) 756-758
12. 3" receptor. Eur. J. Pharmacol. 461 (2003) 27-34
13. Ganellin C.R. Chemistry and structure-activity relationships of drugs acting at histamine receptors. In: Ganellin C.R., and Parsons M.E. (Eds). Pharmacology of Histamine Receptors (1982), John Wright & Sons, Ltd, Bristol 10-102
14. Hough L.B., Nalwalk J.W., Barnes W.G., Warner L.M., Leurs R., Menge W.M.P.B., Timmerman H., and Wentland M. A third life for Burimamide: discovery and characterization of a novel class of non-opioid analgesics derived from histamine antagonists. In: Glick S.D., and Maisonneuve I.M. (Eds). New Medications for Drug Abuse (2000), New York Acad. Sci., New York 25-40
15. Hough L.B., Nalwalk J.W., Chen Y., Schuller A., Zhu Y., Zhang J., Menge W.M.P.B., Leurs R., Timmerman H., and Pintar J.E. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res. 880 (2000) 102-108
16. Hough L.B., Nalwalk J.W., Leurs R., Menge W.M.P.B., and Timmerman H. Antinociceptive activity of derivatives of improgan and burimamide. Pharmacol. Biochem. Behav. 65 (2000) 61-66
17. 3 antagonists and derivatives. J. Pharmacol. Exp. Ther. 283 (1997) 1534-1543
18. Hough L.B., Nalwalk J.W., Barnes W.G., Leurs R., Menge W.M., and Timmerman H. A third legacy for Burimamide: discovery and characterization of improgan and a new class of non-opioid analgesics derived from histamine antagonists. In: Watanabe T., Timmerman H., and Yanai K. (Eds). Histamine Research in the New Millenium (2001), Elsevier, Amsterdam 237-242
19. Hough L.B., Nalwalk J.W., Menge W.M., Leurs R., and Timmerman H. Significance of GABAergic systems in the action of improgan, a non-opioid analgesic. Life Sci. 68 (2001) 2751-2757
20. 1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. J. Pharmacol. Exp. Ther. 303 (2002) 314-322
21. Hough L.B., Nalwalk J.W., Svokos K., Leurs R., and Timmermann H. Pain-relieving drugs and the brain histaminergic system: multiple analgesic mechanisms from histamine, improgan and cimetidine. Inflamm. Res. 53 Suppl. 1 (2004) S43-S44
22. Hough L.B., Nalwalk J.W., Lu Q., Shan Z., Svokos K., Wentland M.P., and Montero M.J. Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic. Eur. J. Pharmacol. 522 (2005) 38-46
23. Li B.Y., Nalwalk J.W., Barker L.A., Cumming P., Parsons M.E., and Hough L.B. Characterization of the antinociceptive properties of cimetidine and a structural analog. J. Pharmacol. Exp. Ther. 276 (1996) 500-508
24. Li B.Y., Nalwalk J.W., Finkel J.M., Glick S.D., and Hough L.B. SKF92374, a cimetidine analog, produces mechanical and thermal antinociception in the absence of motor impairment. Analgesia 3 (1997) 15-20
25. Li B.Y., Nalwalk J.W., and Hough L.B. Effects of naltrexone and histamine antagonists on the antinociceptive activity of the cimetidine analog SKF92374 in rats. Brain Res. 748 (1997) 168-174
26. 4 receptor agonist. J. Pharmacol. Exp. Ther. 314 (2005) 1310-1321
27. 1 receptor activation. J. Biol. Chem. 279 (2004) 48024-48037
28. Mobarakeh J.I., Nalwalk J.W., Watanabe T., Sakurada S., Hoffman M., Leurs R., Timmerman H., Silos-Santiago I., Yanai K., and Hough L.B. Improgan antinociception does not require neuronal histamine or histamine receptors. Brain Res. 974 (2003) 146-152
29. Nalwalk J.W., Svokos K., Taraschenko O., Leurs R., Timmerman H., and Hough L.B. Activation of brain stem nuclei by improgan, a non-opioid analgesic. Brain Res. 1021 (2004) 248-255
30. Nalwalk J.W., Svokos K., Leurs R., and Hough L.B. Absence of 5-HT3 and cholinergic mechanisms in improgan antinociception. Pharmacol. Biochem. Behav. 80 (2005) 505-510
31. Netti C., Bossa R., Galatulas I., Sibilia V., and Pecile A. Antinociceptive effect of centrally administered cimetidine and dimaprit in the rat. Pharmacology 28 (1984) 262-267
32. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Sydney
33. 2 adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic. Brain Res. 921 (2001) 12-19
34. 3 receptor antagonist; in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 275 (1995) 598-604
35. 3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole. J. Med. Chem. 38 (1995) 266-271
36. Zhu Y., Michalovich D., Wu H.-L., Tan K.B., Dytko G.M., Mannan I.J., Boyce R., Alston J., Tierney L.A., Li X., Herrity N.C., Vawter L., Sarau H.M., Ames R.S., Davenport C.M., Hieble J.P., Wilson S., Bergsma D.J., and Fitzgerald L.W. Cloning, expression and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 59 (2001) 434-441